Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 11/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6893880 | 0.91 | CHRM1 (0.54) | CHRM1GAAKMT2A | |
| SCHEMBL2224496 | 0.90 | GAA (0.55) | CHRM1GAAKMT2A | |
| SCHEMBL12803237 | 0.89 | CHRM1 (0.53) | CHRM1GAAKMT2ACNR2 | |
| SCHEMBL12803453 | 0.87 | CHRM1 (0.72) | CHRM1 | |
| SCHEMBL6890527 | 0.87 | CHRM1 (0.72) | CHRM1 | |
| SCHEMBL6892030 | 0.86 | CHRM1 (0.52) | CHRM1BRD4 | |
| SCHEMBL6891432 | 0.85 | CHRM1 (0.51) | CHRM1BRD4KMT2A | |
| SCHEMBL6890113 | 0.84 | CHRM1 (0.49) | CHRM1BRD4 | |
| SCHEMBL12802941 | 0.82 | CHRM1 (0.70) | CHRM1 | |
| SCHEMBL12072483 | 0.82 | CHRM1 (0.47) | CHRM1BRD4KMT2ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2512243-B1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2016-04-06 | — | — | EP | claimed |
| US-20160075656-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2016-03-17 | — | — | US | claimed |
| US-9199939-B2 | Quinoline amide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2015-12-01 | — | — | US | claimed |
| EP-2512243-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck Sharp & Dohme Corp. (US) | 2012-10-24 | — | — | EP | claimed |
| US-20120252808-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-10-04 | — | — | US | claimed |
| WO-2011084368-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | claimed |
| EP-2512243-B1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2016-04-06 | — | — | EP | disclosed |
| US-20160075656-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2016-03-17 | — | — | US | disclosed |
| US-20160075656-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2016-03-17 | — | — | US | disclosed |
| US-9199939-B2 | Quinoline amide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199939-B2 | Quinoline amide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199939-B2 | Quinoline amide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20120252808-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-10-04 | — | — | US | disclosed |
| US-20120252808-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-10-04 | — | — | US | disclosed |
| US-20120252808-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-10-04 | — | — | US | disclosed |
| WO-2011084368-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252808-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, CHRM2 | CHRM1 1/4885BRD4 752/4885GAA 2300/4885 |
| US-20160075656-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, CHRM2 | CHRM1 1/4885BRD4 835/4885GAA 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.